BioSpace News Archive

ProMetic announced today that an orphan drug designation status has been granted to its Plasminogen for the treatment of IPF by the FDA.

Financial terms of the transaction were not disclosed.

This new clearance builds on the recent executive summary published by the College of American Pathologists (CAP) which highlighted the potential value of in vivo microscopy (IVM).

The board of directors of Pfizer Inc. today declared a 34-cent first-quarter 2018 dividend on the company’s common stock, payable March 1, 2018.

Genmab announced today that at a board meeting the board decided to grant 49,680 restricted stock units to members of the board of directors, management and employees of the company as well as the company’s subsidiaries and 139,597 warrants to management and employees of the company as well as the company’s subsidiaries.

Transgene will meet institutional investors from January 7 to 11, 2018, in San Francisco, USA, concurrent with the J.P. Morgan Healthcare conference.

The first stage of the clinical trial, in 8 patients with EGFR mutations, has produced very encouraging results in terms of product safety, dosage and fixing on pulmonary tumors expressing mutated EGFR.

Repros today announced that following an Oral Explanation, it has received feedback that a negative opinion is likely to be received in January 2018 from the CHMP for the centralized MAA for enclomiphene for the treatment of secondary hypogonadism previously submitted to the EMA by the Company’s U.K. subsidiary, Renable Pharma Limited.

This award represents the council’s largest life science investment in New York City this year.

Following up on Mr. Steel’s resignation, the number of Board of Director seats has been reduced to five.